QBiotics is an Australian life sciences company, inspired by nature to improve human and animal health.
Our research and development program is based on compounds derived from the Australian tropical rainforest. Our product focus address unmet medical needs for humans and companion animals. We are currently concentrating on the global health priority areas of cancer, specifically solid tumours, and chronic wound management.
Our oncology product, EBC-46 (tigilanol tiglate), is a new approach to the treatment of solid tumour cancers. Results from human and veterinary clinical trials are supporting the drugs significant potential as an anticancer treatment. Development of tigilanol tiglate is making sound progress and plans are already underway for marketing the veterinary drug in the USA and Europe. Our wound healing product, EBC-1013 (WH-1), is addressing the problem of chronic wounds in a totally new way. Preclinical and early veterinary clinical development with WH-1 is proving to be most promising.
Location: Australia, Queensland, Brisbane City
Member count: 11-50
Founded date: 2004
Investors 1
| Date | Name | Website |
| - | TDM Asset ... | tdmgrowthp... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 25.07.2022 | US FDA APP... | Investigational new drug (IND)... | - | - | en.prnasia... |
| 16.12.2021 | AUSTRALIAN... | QBiotics commences the Austral... | - | - | en.prnasia... |
| 07.07.2021 | New Cancer... | STELFONTA® (tigilanol tiglate)... | - | - | en.prnasia... |
| 28.06.2021 | Qbiotics c... | Capital raise nets $85 million... | - | - | en.prnasia... |
| 03.06.2021 | First Pati... | First patient dosed with QBiot... | - | - | en.prnasia... |